Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.58 |
| ▸ | ABL1 | P00519 | 11/20 | 0.54 |
| ▸ | BCR | P11274 | 9/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.52 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | PRKCA | P17252 | 3/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984112 | 0.91 | CAMKK2 (0.70) | CAMKK2ABL1BCRSRCPDGFRA | |
| SCHEMBL22169871 | 0.89 | CAMKK2 (0.59) | CAMKK2ABL1BCRSRCPDGFRA | |
| SCHEMBL22169842 | 0.88 | CAMKK2 (0.63) | CAMKK2ABL1BCRPDGFRAPDGFRB | |
| SCHEMBL534524 | 0.88 | ABL1 (0.72) | ABL1BCRSRCPDGFRAPDGFRB | |
| SCHEMBL4904288 | 0.87 | CAMKK2 (0.71) | CAMKK2ABL1BCRPDGFRAPDGFRB | |
| SCHEMBL3359717 | 0.84 | ABL1 (0.55) | CAMKK2ABL1BCRSRCPDGFRA | |
| SCHEMBL22169836 | 0.83 | ABCB1 (0.56) | CAMKK2ABL1BCRSRCPDGFRA | |
| SCHEMBL3362224 | 0.81 | KDM4E (0.51) | CAMKK2ABL1BCRSRCPDGFRA | |
| SCHEMBL3358954 | 0.81 | SYK (0.69) | CAMKK2ABL1BCRSRCPDGFRA | |
| SCHEMBL4905638 | 0.81 | PDGFRA (0.67) | ABL1BCRPDGFRAPDGFRBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | Cardio Therapeutics Pty Ltd (AU) | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002271-A1 | HETEROCYCLIC INHIBITORS OF PCSK9 | PCSK9, PCSK6, PCSK7 | CAMKK2 3448/4885ABL1 2347/4885BCR 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.